Evidence map›Paper›PMID 39843760›Full record

Reviewnpj antimicrobials and resistance2024

Policy options for sustainable access to off-patent antibiotics in Europe.

Dimitra Panteli, Michael Anderson, Thomas Fieldman, Enrico Baraldi, Thomas Tängdén, Sabine Vogler, Christine Årdal, Elias Mossialos

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in npj antimicrobials and resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dimitra PanteliEuropean Observatory on Health Systems and Policies, Brussels, Belgium.
Michael AndersonHealth Organisation, Policy, Economics (HOPE), Centre for Primary Care & Health Services Research, The University of Manchester, Manchester, UK. michael.anderson-3@manchester.ac.uk.ORCID http://orcid.org/0000-0002-8454-4640
Thomas FieldmanDepartment of Clinical Microbiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Enrico BaraldiDepartment of Business Studies, Uppsala University, Uppsala, Sweden.
Thomas TängdénDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Sabine VoglerWHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute), Vienna, Austria.
Christine ÅrdalAntimicrobial Resistance Centre, Norwegian Institute of Public Health, Oslo, Norway.
Elias MossialosLSE Health, Department of Health Policy, London School of Economics and Political Science, London, UK.ORCID http://orcid.org/0000-0001-8664-9297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Securing sustainable access to existing antibiotics optimises agent choice for individual treatments and is crucial to curb antibiotic resistance. Access to antibiotics is often restricted in many countries, due to general market unavailability or episodic shortages. This article outlines key policy options to maintain availability of existing antibiotics and enhance antibiotic supply chain resilience focusing on the perspectives of European Union (EU) and European Economic Area (EEA) institutions and member states.

Identifiers

PMID39843760
PMCPMC11721339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.